Press coverage about Cumberland Pharmaceuticals (NASDAQ:CPIX) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 49.1163820026408 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Separately, B. Riley began coverage on shares of Cumberland Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating and a $9.25 price objective for the company.
CPIX stock traded down $0.20 during trading on Thursday, hitting $6.70. The company had a trading volume of 117,514 shares, compared to its average volume of 15,268. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.50 and a current ratio of 3.88. Cumberland Pharmaceuticals has a 12 month low of $5.39 and a 12 month high of $7.96.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, March 6th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 19.39% and a negative return on equity of 1.55%. The firm had revenue of $11.65 million during the quarter.
TRADEMARK VIOLATION WARNING: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/19/cumberland-pharmaceuticals-cpix-earns-media-impact-score-of-0-02.html.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.